News

Sanofi’s Infilbray is designed to cross the blood-brain barrier, allowing the drug to prevent the toxic buildup of disease-causing lipids in the brain.
FEATURED STORIES
IPO
BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.
Acquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” according to one biotech consultant.
The Trump administration withdrew the nomination of Heidi Overton for FDA commissioner Tuesday evening, reportedly due to opposition from Republican Senators.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Watching the baseball playoffs this week, I was struck by the parallels between the Los Angeles Dodgers and Eli Lilly. Both franchises spend a lot of money and always appear to come out on top.
THE LATEST
Biogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approval based on a positive subgroup signal.
Merck is canning multiple Phase 3 studies of nemtabrutinib after a benefit-risk review derailed hopes of the asset entering the non-covalent BTK inhibitor race.
Layoffs at the FDA, disruptions to research funding and increased tariffs led the investment banking firm Cassel Salpeter to wonder whether the government is strangling the biotech industry.
The Chinese biotech will work with Pfizer on three in vivo CAR T therapies for autoimmune indications.
Speaking at the Jefferies conference in London, Pfizer CEO Albert Bourla warned of China’s rise and spoke to how companies like his can compete by leveraging AI-discovered savings.
Nelkarmi is one of two bounties from GSK’s $10.6 billion acquisition of Nuvalent Bio—the other being the ROS1 inhibitor zidesamtinib, which won FDA approval earlier this year as Jideytro.
Summit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population.
The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech history; ObesityWeek and Clinical Trials on Alzheimer’s Disease conferences in full swing.
Your previous employer may have set a high standard. Executive coach Angela Justice explains how holding every company to it can distort your judgment and undermine your influence.
After securing $2.1 billion this May, AI-driven drug designer Isomorphic Labs is back with more money—a lot more—securing the industry’s largest private fundraise ever.